Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver Injury

[1] D'Amico G(2006)Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol. 44 217-231

[2] Garcia-Tsao G(2017)Rationale for the use of statins in liver disease Am J Physiol Gastrointest Liver Physiol. 312 G407-G412

[3] Pagliaro L(2010)Coronary artery disease in patients with liver cirrhosis Dig Dis Sci. 55 467-475

[4] Schierwagen R(2015)High rate of cardiac abnormalities in a postmortem analysis of patients suffering from liver cirrhosis J Clin Gastroenterol. 49 866-872

[5] Uschner FE(2018)Pronounced coronary arteriosclerosis in cirrhosis: Influence on cardiac function and survival? Dig Dis Sci. 63 1355-1362

[6] Magdaleno F(2014)2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol. 63 2889-2934

[7] Kalaitzakis E(2012)New therapeutic paradigm for patients with cirrhosis Hepatology. 56 1983-1992

[8] Rosengren A(2010)Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians Am J Med Sci. 340 89-93

[9] Skommevik T(2007)Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology. 46 1453-1463

[10] Wehmeyer MH(2006)An assessment of statin safety by hepatologists Am J Cardiol. 97 77C-81C

[1] D'Amico G(2006)Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol. 44 217-231

[2] Garcia-Tsao G(2017)Rationale for the use of statins in liver disease Am J Physiol Gastrointest Liver Physiol. 312 G407-G412

[3] Pagliaro L(2010)Coronary artery disease in patients with liver cirrhosis Dig Dis Sci. 55 467-475

[4] Schierwagen R(2015)High rate of cardiac abnormalities in a postmortem analysis of patients suffering from liver cirrhosis J Clin Gastroenterol. 49 866-872

[5] Uschner FE(2018)Pronounced coronary arteriosclerosis in cirrhosis: Influence on cardiac function and survival? Dig Dis Sci. 63 1355-1362

[6] Magdaleno F(2014)2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol. 63 2889-2934

[7] Kalaitzakis E(2012)New therapeutic paradigm for patients with cirrhosis Hepatology. 56 1983-1992

[8] Rosengren A(2010)Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians Am J Med Sci. 340 89-93

[9] Skommevik T(2007)Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial Hepatology. 46 1453-1463

[10] Wehmeyer MH(2006)An assessment of statin safety by hepatologists Am J Cardiol. 97 77C-81C